Owing to the increasing prevalence of peripheral artery diseases (PAD) due to an ageing population, sedentary lifestyles, poor eating habits, and growing demand for non-invasive endovascular procedures, the atherectomy devices market in China is projected to grow at a compound annual growth rate (CAGR) of 9% between 2023 and 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData’s report, “Atherectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that China was the second-largest atherectomy devices market in the Asia-Pacific region by value in 2023, making up to almost 16% of the total market in the region.

Rachna Tripathi, Medical Devices Analyst at GlobalData, comments: “There is an urgent need for innovative solutions to manage significant burden of PAD in China. This need creates substantial growth and expansion opportunities for both local and international players investing in China’s atherectomy devices market.”

Against this background, in March 2024, Avinger Inc, entered into a strategic partnership with Zylox-Tonbridge to localize and distribute its Optical Coherence Tomography (OCT)-guided devices throughout Greater China.

This collaboration offers Avinger a substantial investment opportunity to expand its coverage in the Chinese market as well as the chance to distribute premium peripheral vascular products made by Zylox in Germany and the US. This partnership will allow Zylox to address the rising disease burden in China by offering more affordable and superior OCT-guided vascular treatment solutions.

Tripathi concludes: “Steep learning curve for healthcare professionals, high costs, and side effects such as distal embolization, vascular trauma, and increased procedural time are some of the challenges in this market. Strategic partnerships to advance technology, accessibility, affordability, safety, and user-friendliness are expected to address these challenges and propel market growth.”